Unknown

Dataset Information

0

Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.


ABSTRACT:

Background

Long QT syndrome type 3 (LQT3) accounts for 5%-10% of long QT syndrome and results from gain-of-function mutations in the SCN5A-encoded sodium channel. Approximately 2% of healthy individuals host rare SCN5A variants of uncertain significance (VUS). Distinction of true LQT3-causative mutations from background genetic noise is essential.

Objective

The purpose of this study was to assess the use of the lidocaine attenuation test (LAT) in evaluating patients with possible LQT3.

Methods

We reviewed the LAT results and medical records for 25 patients with a possible LQT3-associated SCN5A variant. The LAT involved a loading dose of 1 mg/kg of intravenous lidocaine followed by continuous infusion at 50 μg/(kg⋅min) for 20 minutes. If the corrected QT interval shortened by ≥30 ms, the LAT was defined as positive.

Results

Sixteen patients (64%) had a positive LAT, 6 of which demonstrated the E1784K variant. A positive LAT correlated in 86% of cases with abnormal in vitro channel function (mean corrected QT interval attenuation 43 ± 3 ms vs 25 ± 5 ms for wild-type variants; P = .03). Four of 5 patients (80%) with a VUS had a positive LAT (T1304M [2 patients], L1786P, and R800L). The T1304M variant demonstrated abnormal in vitro function and a positive LAT, opening the door for a potential variant promotion from VUS to likely pathogenic.

Conclusion

The LAT may help distinguish true LQT3-causative mutations from an otherwise noncontributory VUS. Given that lidocaine acts as a late sodium current blocker, a positive LAT may enable the early identification of a pathological accentuation of the late sodium current that could be targeted therapeutically.

SUBMITTER: Anderson HN 

PROVIDER: S-EPMC6590893 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.

Anderson Heather N HN   Bos J Martijn JM   Kapplinger Jamie D JD   Meskill Jana M JM   Ye Dan D   Ackerman Michael J MJ  

Heart rhythm 20170413 8


<h4>Background</h4>Long QT syndrome type 3 (LQT3) accounts for 5%-10% of long QT syndrome and results from gain-of-function mutations in the SCN5A-encoded sodium channel. Approximately 2% of healthy individuals host rare SCN5A variants of uncertain significance (VUS). Distinction of true LQT3-causative mutations from background genetic noise is essential.<h4>Objective</h4>The purpose of this study was to assess the use of the lidocaine attenuation test (LAT) in evaluating patients with possible  ...[more]

Similar Datasets

| S-EPMC4688076 | biostudies-literature
| S-EPMC4878676 | biostudies-literature
| S-EPMC3150844 | biostudies-literature
| S-EPMC1773013 | biostudies-literature
| S-EPMC2691533 | biostudies-other
| S-EPMC3065994 | biostudies-literature
| S-EPMC8897185 | biostudies-literature
| S-EPMC7756571 | biostudies-literature
| S-EPMC198523 | biostudies-literature
2020-05-09 | GSE150134 | GEO